Starpharma, AstraZeneca sign cancer drug agreement

Starpharma, AstraZeneca sign cancer drug agreement

5:55 AM, 6th September 2012
Starpharma, AstraZeneca sign cancer drug agreement

MELBOURNE, AUSTRALIA: Starpharma Holdings Ltd signed an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology. AstraZeneca will undertake oncology studies using specific Starpharma drug-dendrimer conjugate molecules.

The primary objective of the programme is to access the suitability of the dendrimer constructs for particular applications within the cancer field. The identity of the anti-cancer molecules to be studied is covered by confidentiality restrictions, but Starpharma notes that the arrangement does not relate to docetaxel or to dendrimer conjugates of docetaxel. Further details of the arrangement between the parties were not disclosed.

© WOC News 



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Orascom to invest $1.4 billion in fertilizer plant in Iowa, US

CAIRO, EGYPT: Egypt’s Orascom Construction Industries plans to invest $1.4 billion in a fertilizer plant in Iowa, US shunning overtures from nei ...

Read more
FMC, BCEER, BRISEA JV to market environmental technologies in China

PHILADELPHIA, US: FMC Corporation, BCEG Environmental Remediation Co Ltd (BCEER), and BRISEA Group Inc, have signed a definitive agreement to form a j ...

Read more
Clariant, Emerald Technology Ventures partner for cleantech sector

MUTTENZ, SWITZERLAND: Swiss specialty chemicals group, Clariant entered into a partnership agreement with Emerald Technology Ventures. Clariant will c ...

Read more
Scientists show way to improved water-splitting catalysts

CALIFORNIA, US: Scientists and engineers around the world are working to find a way to power the planet using solar-powered fuel cells. Such green sys ...

Read more
Bayer CropScience, Mendel to co-develop herbicide resistance breaking technology

MONHEIM, GERMANY: Bayer CropScience and Mendel Biotechnology Inc Hayward, California, USA have agreed for a new multi-year collaboration to jointly id ...

Read more
Linde launches €1 billion bond

MUNICH, GERMANY: Linde AG has successfully placed €1 billion of senior notes with an 8-year maturity. The bond, with a coupon of 1.75 per cent is ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X